SEARCH

SEARCH BY CITATION

References

  • 1
    National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
  • 2
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 2004; 351: 438-450.
  • 3
    Ohto H, Terazawa S, Sasaki N, Sasaki N, Hino K, Ishiwata C, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330: 744-750.
  • 4
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 5
    Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-1226.
  • 6
    Thomas DL, Astemborski J, Vlahov D, Strathdee SA, Ray SC, Nelson KE, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000; 181: 844-851.
  • 7
    Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 1337-1344.
  • 8
    Tseng FC, Edlin BR, Zhang M, Kral A, Busch MP, Ortiz-Conde BA, et al. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008; 15: 690-698.
  • 9
    Tseng FC, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46: 666-671.
  • 10
    Atkinson J, Edlin BR, Engels EA, Kral AH, Seal K, Gamache CJ, et al. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 2003; 187: 974-981.
  • 11
    Seal KH, Kral AH, Lorvick J, Gee L, Tsui JI, Edlin BR. Among injection drug users, interest is high, but access low to HCV antiviral therapy. Society of General Internal Medicine, 28th annual meeting, New Orleans, Louisiana, USA, May 11-14, 2005. J Gen Intern Med 2005; 20(Suppl 1): 171.
  • 12
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
  • 13
    Eyster M, Fried M, Di Bisceglie A, Goedert J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84: 1020-1023.
  • 14
    Gordon SC, Dailey PJ, Silverman AL, Khan BA, Kodali VP, Wilber JC. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification. Hepatology 1998; 28: 1702-1706.
  • 15
    Hollingsworth RC, Sillekens P, van Deursen P, Neal KR, Irving WL. Serum HCV RNA levels assessed by quantitative NASBA®: stability of viral load over time, and lack of correlation with liver disease. J Hepatol 1996; 25: 301-306.
  • 16
    Yeo AET, Ghany M, Conry-Cantilena C, Melpolder JC, Kleiner DE, Shih JWK, et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 256-263.
  • 17
    McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, et al. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 2004; 39: 325-332.
  • 18
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477.
  • 19
    Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011; 18: e134-e143.
  • 20
    Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001; 26: 466-472.
  • 21
    Telfer PT, Brown D, Devereux H, Lee CA, Sheiko GMD. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. Brit J Haematol 1994; 88: 397-399.
  • 22
    Beld M, Penning M, Lukashov V, McMorrow M, Roos M, Pakker N, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998; 244: 504-512.
  • 23
    Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 2679-2682.
  • 24
    Rauch A, Gaudieri S, Evison J, Nolan D, Cavassini M, Weber R, et al. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV Cohort Study. Antivir Ther 2008; 13: 455-460.
  • 25
    Shebl FM, Pfeiffer RM, Buckett D, Muchmore B, Chen S, Dotrang M, et al. IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis 2011; 204: 1843-1847.
  • 26
    Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.e1337.
  • 27
    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
  • 28
    Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592.e1581.
  • 29
    Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224.
  • 30
    Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
  • 31
    McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
  • 32
    Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Hernandez-Quero J, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011; 25: 761-766.
  • 33
    Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
  • 34
    Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
  • 35
    Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 1915-1923.
  • 36
    Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
  • 37
    Chen Z, Weck KE. Hepatitis C virus genotyping: interrogation of the 5′ untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 2002; 40: 3127-3134.
  • 38
    Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112.
  • 39
    Tamalet C, Colson P, Tissot-Dupont H, Henry M, Tourres C, Tivoli N, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003; 71: 391-398.
  • 40
    Johnson YNL, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995; 171: 281-289.
  • 41
    Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31.